- Home
- IMXI vs PHAR Comparison
IMXI vs PHAR Comparison
Compare IMXI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- PHAR
- Stock Information
- Founded
- IMXI 1994
- PHAR 1988
- Country
- IMXI United States
- PHAR Netherlands
- Employees
- IMXI N/A
- PHAR N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- IMXI Technology
- PHAR Health Care
- Exchange
- IMXI Nasdaq
- PHAR Nasdaq
- Market Cap
- IMXI 302.5M
- PHAR 731.1M
- IPO Year
- IMXI N/A
- PHAR N/A
- Fundamental
- Price
- IMXI $10.23
- PHAR $10.31
- Analyst Decision
- IMXI Buy
- PHAR Strong Buy
- Analyst Count
- IMXI 7
- PHAR 3
- Target Price
- IMXI $19.60
- PHAR $30.00
- AVG Volume (30 Days)
- IMXI 327.7K
- PHAR 3.6K
- Earning Date
- IMXI 08-06-2025
- PHAR 07-31-2025
- Dividend Yield
- IMXI N/A
- PHAR N/A
- EPS Growth
- IMXI 1.60
- PHAR N/A
- EPS
- IMXI 1.70
- PHAR N/A
- Revenue
- IMXI $652,547,000.00
- PHAR $320,708,000.00
- Revenue This Year
- IMXI N/A
- PHAR $13.31
- Revenue Next Year
- IMXI $2.93
- PHAR $7.68
- P/E Ratio
- IMXI $6.04
- PHAR N/A
- Revenue Growth
- IMXI N/A
- PHAR 24.13
- 52 Week Low
- IMXI $9.76
- PHAR $6.65
- 52 Week High
- IMXI $22.38
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- IMXI 45.62
- PHAR 43.60
- Support Level
- IMXI $10.10
- PHAR $9.99
- Resistance Level
- IMXI $10.87
- PHAR $10.49
- Average True Range (ATR)
- IMXI 0.33
- PHAR 0.34
- MACD
- IMXI 0.05
- PHAR -0.14
- Stochastic Oscillator
- IMXI 51.35
- PHAR 7.45
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.